Sinovac to trial COVID-19 vaccine in South African children in global study
The Peninsula
JOHANNESBURG: China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday.
The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement. The global trial will enroll 14,000 participants across Chile, the Philippines, Malaysia, Kenya including 2,000 in South Africa, they said.More Related News